Companies’ ongoing collaboration to advance in vivo genetic medicines using Scribe’s CRISPR by Design™ approach broadens with Sanofi’s selection of a second target ALAMEDA, Calif.--(BUSINESS ...
Companies’ ongoing collaboration to advance in vivo genetic medicines using Scribe’s CRISPR by Design™ approach broadens with Sanofi’s selection of a second target “We are pleased to advance our ...
Milestone achieved in Scribe and Lilly’s ongoing collaboration to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular diseases Achievement validates Scribe’s technologies and ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する